Skip to Main Content

Paper Details

Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors.
Blood Cancer Discov
50
2021
Author NameAffiliation
Rashmi Kanagal-ShamannaThe University of Texas MD Anderson Cancer Center
Courtney D DiNardoThe University of Texas MD Anderson Cancer Center
Gautam BorthakurThe University of Texas MD Anderson Cancer Center
Guillermo Garcia-ManeroThe University of Texas MD Anderson Cancer Center
Jorge CortesGeorgia Cancer Center, Augusta University
Farhad RavandiThe University of Texas MD Anderson Cancer Center
  • 1 - 6

Datasets

Release 1.2